CClinicalTrials.gg
WithdrawnNCT02996942KAPPAUpdated Dec 21, 2018

Key Aspects of Medical Practice in Patients With Haemophilia A

An observational study in Joint Disease, sponsored by Lund University. Withdrawn. Per ClinicalTrials.gov, last updated 2018-12-21.

Sponsored by Lund University · Observational

Why this study was withdrawn
Not active
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
0
Sex
All
01

Study summary

The KAPPa project has the aim to create an international database in which information about clinical features, therapeutic management, burden of illness and costs of severe and moderate haemophilia A patients from different countries and sites is collected. The aim of this project is to analyse the influence of such different characteristics on medical, psychosocial and economic outcomes in patients over the long-term.

Read the detailed description

1000 patients with hemophilia A will be enrolled using a webbased registry. Key quality factors that will be registered are : hemophilia joint Health score (HJHS), annual bleed rate, quality of Life (EQ5D), as well as dosing of replacement therapy.

02

Conditions studied

  • Joint Disease

Keywords

  • haemophilia, joint disease, quality of life
03

In context

Joint Diseases

712 studies on the registry are indexed under Joint Diseases; 127 are open to participants now.

Browse Joint Diseases studies →

Lead sponsor

Lund University is the lead sponsor of 230 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients from haemophilia centers.

Eligibility criteria

Inclusion Criteria: or forms.

  • severe haemophilia A (factor VIII\<1%)
  • moderate (factor VIII\<5%)
  • signed informed consent

Exclusion Criteria:

  • Not fullfilling inclusion criteria
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
0 participants (actual)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • Replacement therapy

    Hemophilia A receiving replacement therapy (prophylaxis or on demand)

    Biological: Factor VIII replacement

Interventions

  • BiologicalFactor VIII replacement

    Patients receive their usual treatment

    Also known as: factor VIII

06

What researchers measure

Primary outcomes

  1. Outcome of factor replacement treatment

    Joint disase according to HJHS. Quality of Life. Health economic evalaution.

    Time frame: 3 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02996942
Lead sponsor
Lund University
Responsible party
Sponsor
First posted
Dec 19, 2016
Start date
Jul 2012
Primary completion
Dec 2017 (estimated)
Completion
Dec 2017 (estimated)
Last update
Dec 21, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion